Thermo Fisher Introduces New Blood-Matching Array and Software

Thermo Fisher Scientific, an AABB corporate partner, recently introduced the Applied Biosystems Axiom BloodGenomiX Array and Software, a first-of-its-kind solution for more precise blood genotyping in clinical research.

The new array covers more than 40 genes and 260 antigens across 38 blood group systems in a single, high-throughput assay. It also detects tissue (HLA) and platelet (HPA) types. Validation studies have demonstrated its accuracy, with a concordance rate of 99.89% with participants' blood group antigen types.

The Axiom BloodGenomiX Array was developed in collaboration with the Blood Transfusion Genomics Consortium (BGC), an international partnership between Thermo Fisher, the New York Blood Center Enterprises (NYBCe) and an international group of blood services, research institutions and industry leaders. The BGC aims to improve the safety and efficacy of blood and platelet transfusion by introducing cutting-edge genomics technology into routine clinical practice.

“We have an amazing team working together to reshape the future of blood typing. Our goal is to develop an affordable and scalable solution that can one day be embedded across labs globally,” said Connie Westhoff, PhD, SBB, BGC deputy chair and representive of the National Center for Blood Group Genomics at the NYBCe. “Our vision is to one day make comprehensive blood typing for all donors and patients the standard of care.”

Additional information about the Axiom BloodGenomiX Array and Software is available online.